4.8 Article

Tandem reassembly of split luciferase-DNA chimeras for bioluminescent detection of attomolar circulating microRNAs using a smartphone

Journal

BIOSENSORS & BIOELECTRONICS
Volume 173, Issue -, Pages -

Publisher

ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2020.112824

Keywords

Circulating microRNAs; Split luciferase reassembly; Bioluminescence; Smartphone-based detection; Point-of-care diagnostics

Funding

  1. National Natural Science Foundation of China [21405181, 31670372]
  2. Fundamental Research Funds for the Central Universities [CZQ20001]
  3. Health Commission of Hubei Province [WJ 2019F164]
  4. Tanhualin Student of Hubei Provincial Hospital of Traditional Chinese Medicine [P-20190319-0535]

Ask authors/readers for more resources

A DNA-guided bioluminescence strategy was developed for the detection of dysregulated circulating miRNAs with high sensitivity and reliability. This method allows smartphone-based miRNA assays, making it suitable for resource-limited regions, and accurately identifies abnormal miRNAs in clinical samples from lung cancer patients.
Detection of dysregulated circulating microRNAs (miRNAs) in human biofluids is a fundamental ability to determine tumor occurrence and metastasis in a minimally invasive fashion. However, the requirements for sophisticated instruments and professional personnel impede the translation of miRNA tests into routine clinical diagnostics, especially for resource-limited regions. Herein, we developed a DNA-guided bioluminescence strategy for the detection of circulating miRNAs. In this strategy, a pair of split luciferase-DNA chimeras was constructed and integrated into the miRNA-triggered rolling circle amplification (RCA) process. The tandem reassembly of split luciferase-DNA chimeras on the RCA products elicited a turn-on bioluminescence response with ultrahigh signal-to-background (S/B) ratio. This strategy enabled smartphone-based assays for different miRNAs with attomolar sensitivity and single-base specificity, as demonstrated here for miR-21. miR-148b, and cel-miR-39. Further application of our approach to the clinical serum samples realized identification of dysregulated miR-21 and miR-148b in the lung cancer patients, showing a satisfactory agreement with the control assays performed with quantitative reverse transcription polymerase chain reaction (qRT-PCR). Therefore, the developed method possesses the benefits of high performance and reliability, offering a potential tool for implementing miRNA-based diagnosis in point-of-care (POC) settings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available